SUNNYVALE, Calif., Sept. 16, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced that, on September 11, 2019, China's Customs Tariff Commission of the State
Council issued a tariff exemption for medical linear
accelerators. The tariff exemption, which will be effective
September 17, 2019 and is scheduled
to last for one year, applies to the additional tariffs
China imposed on U.S. products
effective as of August 23, 2018.
Accuray expects to benefit from such tariff exemption.
"We applaud the recent decision to exempt medical linear
accelerators," said Josh Levine,
president and chief executive officer, Accuray. "We believe that
this exemption will enable commercial momentum for our joint
venture, CNNC Accuray (Tianjin)
Medical Technology Co., Ltd, to expand access to our precise,
innovative radiation therapy systems for hospitals and patients in
China."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations regarding the
company's and the joint venture's ability to benefit from the
expected exemption from tariffs in China. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking
statements.
These risks and uncertainties include, but are not limited to,
the company's ability to receive and maintain eligibility for the
tariff exemption for medical linear accelerators, the continued
applicability of the tariff exemption to our products in the
future, the company's ability to realize the expected benefits of
the joint venture, the company's ability to achieve widespread
market acceptance of its products and such other risks identified
under the heading "Risk Factors" in the company's annual report on
Form 10-K, filed with the Securities and Exchange Commission (the
"SEC") on August 23, 2019, and as
updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Michael Polyviou
Investor Relations, EVC Group
+1 (732) 933-2755
mpolyviou@evcgroup.com
Media Contact:
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/china-announces-tariff-exclusion-for-medical-linear-accelerators-300918431.html
SOURCE Accuray Incorporated